Economy

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Rating Reaffirmed by Stifel Nicolaus

The institutional investor owned 1,221,338 shares of the biopharmaceutical company's stock after selling 20,000 shares during the quarter.

Heading into the stock price potential, EdR needs to grow just 7.47% to cross its median price target of $41.

In the most updated research from a number of analysts on Wall Street, the company gets 11 Buys and 1 Sell among 18 analysts.

Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 112.92 on Wednesday.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)'s earnings per share has been growing at a -28.7 percent rate over the past 5 year when average revenue increase was noted as -10.6 percent. Finally, Chardan Capital reiterated a "buy" rating and set a $131.00 target price (up previously from $110.00) on shares of Alnylam Pharmaceuticals in a report on Monday, July 10th. Morgan Stanley upped their price objective on Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the company an equal weight rating in a research report on Thursday, August 10th. BidaskClub lowered Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, August 16th. (NASDAQ:ALNY). This is based on a 1-5 scale where 1 indicates a Strong Buy and 5 a Strong Sell. The consensus analyst target price is $88.63.

Alnylam Pharmaceuticals (NASDAQ ALNY) traded up 3.450% during trading on Friday, hitting $116.816.

At the time of writing, the stock was trading at $1.69. Alnylam Pharmaceuticals, Inc. The firm has a 50-day moving average of $81.14 and a 200-day moving average of $69.12. Alnylam Pharmaceuticals has a 52-week low of $31.38 and a 52-week high of $118.40. The company has market cap of $10.54 billion. Alnylam Pharmaceuticals also was the target of some unusual options trading on Wednesday. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. This represents an increase of 937% compared to the average volume of 2,944 call options. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. September 21 investment analysts at Leerink Swann kept the company rating at "Outperform" but raised the price expectation from $50.00 to $123.00. During the same period in the previous year, the business posted ($1.05) EPS. The company's revenue for the quarter was up 82.9% on a year-over-year basis. On average, equities research analysts predict that Alnylam Pharmaceuticals will post ($5.20) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and reposted in violation of USA and worldwide trademark & copyright legislation. FMR LLC grew its stake in Alnylam Pharmaceuticals by 6.3% in the 2nd quarter.

Investors are feeling more bullish on shares of the company of late if you watch the decrease in short interest. Wellington Management Group LLP grew its stake in Alnylam Pharmaceuticals by 0.3% in the 1st quarter. The Manufacturers Life Insurance Company increased its position in shares of Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company's stock valued at $203,000 after buying an additional 167 shares during the last quarter. BlackRock Inc. grew its stake in Alnylam Pharmaceuticals by 9.3% in the 2nd quarter. Manufacturers Life Ins The owns 2,541 shares or 0% of their U.S. portfolio. Finally, Baillie Gifford & Co. grew its stake in Alnylam Pharmaceuticals by 2.9% in the 2nd quarter. The short sellers then promise to replace the stock in the future and makes dividend payments out of their own pockets to cover the dividend income that is no longer exists on the original, now borrowed and sold, shares. The percentage of shares being held by the company management was 0.7% while institutional stake was 89.9%.



Like this

Latest


23 Сентября 2017
Brokers Set Expectations for Westlake Chemical Corporation's Q3 2017 Earnings (WLK)
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website . OppenheimerFunds Inc. purchased a new stake in Westlake Chemical Corporation during the 1st quarter valued at about $205,000.

23 Сентября 2017
Boston Scientific Corp (NYSE:BSX) Institutional Investors Sentiment
Over the last five days, shares have faced -0.72% losses and now is up 12.3% since hitting its 200-day moving average of $26.61. The institutional investors in our partner's database now hold: 1.22 billion shares, down from 1.23 billion shares in 2017Q1.

23 Сентября 2017
Boy, 17, arrested in connection with Parsons Green tube attack
A man in a red hat - carrying a Lidl bag - was also captured by cameras near the Jones's home about 90 minutes before the attack. A suicide bomber attacked a concert venue in Manchester in May, killing more than 20 people including children and mothers.

23 Сентября 2017
US Military Gets Mysterious and False Text Message to Evacuate Korean Peninsula
The US military has an evacuation plan for the peninsula that it has tested on several occasions in order to maintain readiness. The U.S. military command in Korea routinely rehearses such evacuations, typically in the spring and fall.

23 Сентября 2017
Four-star SF Ignas Brazdeikis (2018) commits to MI basketball
Despite his size (6-8, 220 pounds), Brazdeikis will spend most of his time on the wing with the Wolverines . Brazdeikis is known on the AAU circuit for several 50-point outbursts, including two in March.

23 Сентября 2017
Observation about Insider Ownership of: Oasis Petroleum Inc. (NYSE:OAS)
According to the recommendations from 2 analysts stock has mean rating of 3 on the shares of Argos Therapeutics (NASDAQ:ARGS). The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold.

23 Сентября 2017
North Korean leader: Trump is 'mentally deranged'
President Donald Trump is again assailing North Korea Kim Jong Un , saying that he "will be tested like never before". Ri, who is due to speak to the United Nations on Saturday, added that he did not know Kim's exact thoughts.

23 Сентября 2017
22nd Century (XXII): What are the Technicals Saying?
Defining investment goals clearly can help keep individual investors from making common mistakes and losing their shirts. The older the historical return data is, the more likely it is to be less useful when predicting future returns.

23 Сентября 2017
5 things to know about N. Korean leader's rebuke of Trump
The North Korean leader earlier labelled Trump "mentally deranged" and a "dotard" after Trump threatened to destroy his country. But the speech was textbook Trump , dividing the globe into friends and foes and taking unflinching aim at America's enemies.

23 Сентября 2017
Synchrony Financial (SYF) EPS Estimated At $0.66
Seth Klarman increased its stake in Synchrony Finl ( SYF ) by 65.84% based on its latest 2017Q2 regulatory filing with the SEC. In the most updated research from a number of analysts on Wall Street, the company gets 16 Buys and 0 Sell among 22 analysts.



Recommended